Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) generates a steady flow of corporate, product and governance updates that are relevant to investors following EGRX news. As a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, Eagle regularly issues press releases about its commercial portfolio, pipeline programs and capital structure decisions.
Company announcements describe a portfolio that includes PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO, as well as BYFAVO and BARHEMSYS historically commercialized through its wholly owned subsidiary Acacia Pharma Inc. News items have covered transactions such as a royalty purchase agreement to monetize BENDEKA royalties and the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, with Eagle noting that proceeds would support ongoing operations and debt repayment.
Governance and capital markets developments are also a recurring theme in Eagle’s news flow. The company has reported on the adoption and amendment of a limited duration stockholder rights plan, changes to the plan’s purchase price and duration, and cooperation agreements with significant stockholders involving board appointments. In addition, Eagle issues updates on its annual meeting of stockholders, proxy material availability, and the release of audited and unaudited financial statements.
Investors monitoring EGRX news can use this page to follow Eagle’s disclosures on its oncology and critical care products, CNS/metabolic critical care pipeline, financing transactions, and corporate governance actions. Regularly reviewing these updates can help readers understand how Eagle describes the evolution of its product portfolio, pipeline priorities and capital structure over time.
Summary not available.
Summary not available.
Summary not available.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) has announced a settlement agreement with Dr. Reddy’s Laboratories regarding patent litigation related to its drug BENDEKA®. Under the terms of the settlement, Dr. Reddy’s can market its product starting November 17, 2027, with potential for earlier market entry under specific conditions. This agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. This follows previous settlements with Hospira and Accord Healthcare regarding similar patent claims.
Eagle Pharmaceuticals reported Q4 2022 net income of $8.2 million, or $0.63 per share, compared to a loss of $6.2 million in Q4 2021. Total revenue for Q4 2022 was $60.7 million, an increase from $42.3 million year-over-year. For FY 2022, Eagle achieved net income of $35.6 million, up from a loss of $8.6 million in 2021, with total revenue rising to $316.6 million from $171.5 million. PEMFEXY® achieved $12.1 million in sales in Q4 2022, capturing a 6% market share. The FDA approved PEMFEXY for an additional indication, and the company plans to increase its share to 12% by Q1 2023. Eagle had $55.3 million in cash as of December 31, 2022.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2023, at 2:35 PM ET. This event will take place in Miami, FL, and will be available via webcast. Eagle Pharmaceuticals is committed to innovation in medicines that enhance patients' lives, with a diverse product portfolio and a strong pipeline targeting critical areas in oncology and metabolic care.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) will release its fourth quarter and full year 2022 financial results on March 13, 2023, before the market opens. CEO Scott Tarriff and CFO Brian Cahill will host a conference call at 8:30 a.m. ET to discuss the results. Investors can access the call toll-free at 800-445-7795 (U.S.) or 785-424-1789 (International). A replay will be available for two weeks, and the webcast will be archived for 30 days on the company's website.
Eagle specializes in developing innovative medicines and has a portfolio of commercialized products including vasopressin and BENDEKA®. The company focuses on addressing critical care and oncology needs.
Eagle Pharmaceuticals, Inc. (EGRX) reported a net income of $21.3 million for the year ending September 30, 2022, translating to $1.63 per diluted share. The company's adjusted EBITDA stood at $125.6 million, showing substantial growth from 2021. Eagle aims to double its share of the pemetrexed market with projected quarterly revenues of $8 million. The company anticipates an adjusted EBITDA of $74.0-$80.0 million and adjusted non-GAAP earnings per share of $4.20-$4.53 for 2023. Key product growth is expected, especially in PEMFEXY sales, post royalty adjustments.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 AM PT/1:30 PM ET. The presentation will be available as a webcast for 30 days on the company’s website, allowing investors to access key insights into Eagle’s corporate strategies and product pipeline. The company is recognized for its innovative pharmaceutical solutions aimed at improving patient outcomes, with commercialized products across critical care and oncology.
Eagle Pharmaceuticals (Nasdaq: EGRX) announced FDA approval for an additional indication of PEMFEXY (pemetrexed injection) for treating patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK aberrations. This approval marks the fifth indication for PEMFEXY, a ready-to-use liquid formulation designed to simplify treatment by eliminating reconstitution steps. Additionally, effective October 1, 2022, Eagle amended its agreement, reducing future royalties from 25% to 0%-12.5% in exchange for a $15 million one-time payment.